NewslettersDermal Cell NewsSilencing FOXP2 Reverses Vemurafenib Resistance in BRAFV600E Mutant Papillary Thyroid Cancer and Melanoma CellsBy Laurisa Dohm - November 7, 20220293A vemurafenib-resistant BRAFV600E melanoma cell line was established by gradually increasing the drug concentration.[Endocrine]Full Article